Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment

Description

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market to Reach $7.5 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment estimated at US$2.8 Billion in the year 2022, is projected to reach a revised size of US$7.5 Billion by 2030, growing at aCAGR of 13.1% over the period 2022-2030. Medication, one of the segments analyzed in the report, is projected to record 11% CAGR and reach US$4.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Other Treatments segment is readjusted to a revised 18.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $816.7 Million, While China is Forecast to Grow at 12.6% CAGR

The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market in the U.S. is estimated at US$816.7 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 12.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11% and 11% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 9.3% CAGR.

Select Competitors (Total 42 Featured) -

Achillion Pharmaceuticals
Akari Therapeutics
Alexion Pharmaceuticals
Amgen Inc.
Apellis Pharmaceuticals
F. Hoffmann-La Roche AG.
GE Healthcare
Johnson & Johnson
Ra Pharmaceuticals
Regeneron Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited (Shire Plc)
Thermo Fisher Scientific Inc.

Product Code: MCP22462

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 2: World Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 3: World 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 5: World Historic Review for Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 6: World 16-Year Perspective for Medication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 8: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 9: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- TABLE 10: World Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
- Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- TABLE 11: USA Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 12: USA Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 13: USA 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
CANADA
- TABLE 14: Canada Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 15: Canada Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 16: Canada 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
JAPAN
- Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- TABLE 17: Japan Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 18: Japan Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 19: Japan 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
CHINA
- Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- TABLE 20: China Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 21: China Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 22: China 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
EUROPE
- Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- TABLE 23: Europe Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 24: Europe Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 25: Europe 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- TABLE 26: Europe Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 27: Europe Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 28: Europe 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
FRANCE
- Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- TABLE 29: France Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 30: France Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 31: France 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
GERMANY
- Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- TABLE 32: Germany Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 33: Germany Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 34: Germany 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
ITALY
- TABLE 35: Italy Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 36: Italy Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 37: Italy 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
UNITED KINGDOM
- Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- TABLE 38: UK Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 39: UK Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 40: UK 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
REST OF EUROPE
- TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 42: Rest of Europe Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 43: Rest of Europe 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
ASIA-PACIFIC
- Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 45: Asia-Pacific Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 46: Asia-Pacific 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
REST OF WORLD
- TABLE 47: Rest of World Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 48: Rest of World Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 49: Rest of World 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment

Description

Table of Contents

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION